Aurobindo Pharma Q3 Results: Profit Rises 7.6% to ₹910 Crore, Europe Drives Growth
Aurobindo Pharma reported steady Q3FY26 earnings growth led by strong Europe performance and stable US generics demand.
Aurobindo Pharma Q3 results for the December quarter reflected steady earnings growth, supported by strong traction in European markets and stable performance in the US generics business. The company reported an 8.4% year-on-year increase in revenue and a 7.6% rise in net profit, while maintaining EBITDA margins above 20%. Growth was primarily driven by the Europe formulations segment, which posted strong double-digit expansion, offsetting slower growth in the US due to lower transient product sales. The company also continued to invest in its specialty and biosimilar pipeline, with research and development spending at 4.7% of sales. With a strong net cash position and consistent free cash flow generation during the quarter, Aurobindo remains positioned to fund capacity expansion, biosimilar launches, and new product introductions across regulated markets.
Live Earnings Snapshot — Q3FY26
| Revenue | ₹8,646 crore | ▲ 8.4% YoY |
| EBITDA | ₹1,773 crore | ▲ 9.0% YoY |
| EBITDA Margin | 20.5% | ▲ 11 bps YoY |
| Net Profit | ₹910 crore | ▲ 7.6% YoY |
Source: Company Q3FY26 presentation
Table of Contents
- Key Highlights
- Financial Performance
- Operational Drivers
- Segment Trends
- Capital-Flow Impact
- Valuation Context
- Risks
- Outlook
- Internal Links
- External Links
Aurobindo Pharma Q3 Results: Key Highlights
- Revenue rose 8.4% YoY to ₹8,646 crore.
- EBITDA increased 9.0% YoY to ₹1,773 crore.
- Net profit grew 7.6% YoY to ₹910 crore.
- Europe business recorded strong double-digit growth.
- R&D spend at ₹409 crore, about 4.7% of sales.
- Free cash flow of $118 million during the quarter.
Aurobindo Pharma Q3 Results: Financial Performance
| Metric | Q3FY26 | Q3FY25 | YoY Change |
|---|---|---|---|
| Revenue | ₹8,646 crore | ₹7,979 crore | ▲ 8.4% |
| EBITDA | ₹1,773 crore | ₹1,628 crore | ▲ 9.0% |
| EBITDA Margin | 20.5% | 20.4% | ▲ 11 bps |
| Net Profit | ₹910 crore | ₹846 crore | ▲ 7.6% |
| EPS | ₹15.67 | ₹14.56 | ▲ 7.7% |
Operational Drivers
- Europe revenue increased sharply with strong performance across key markets.
- US generics base business remained stable despite lower transient product sales.
- Seven ANDA approvals and nine product launches in the US during the quarter.
- Net capex of $79 million focused on capacity and new business.
Segment Trends
| Segment | Q3FY26 Revenue | YoY Change |
|---|---|---|
| USA | ₹3,739 crore | ▲ 2.2% |
| Europe | ₹2,703 crore | ▲ 27.4% |
| Growth Markets | ₹865 crore | ▼ 0.9% |
| ARV | ₹376 crore | ▲ 22.4% |
| API | ₹963 crore | ▼ 4.3% |
Europe was the primary growth driver, while API revenues declined due to market conditions.
Capital-Flow Impact
- Free cash flow generated: $118 million in Q3FY26.
- Net cash position of approximately $251 million after acquisition adjustments.
- Continued investment in biosimilars and specialty pipeline.
- R&D intensity maintained at 4.7% of sales.
Valuation Context
Aurobindo Pharma continues to trade as a large-cap global generics exporter with diversified exposure across the US, Europe, growth markets, and antiretroviral therapies. The company’s EBITDA margins have remained stable around the 20% level, supported by operating efficiencies, scale benefits, and improvements in product mix.
Stable EBITDA margins around the 20% level, strong Europe growth offsetting US pricing pressure, and a net cash position supporting expansion together form the key pillars of the company’s current valuation framework.
Key Risks
- US generics pricing pressure.
- Regulatory risks in key manufacturing facilities.
- Execution risks in biosimilar pipeline.
- Currency fluctuations impacting export earnings.
Aurobindo Pharma Q3 Results: Outlook
- Europe expected to remain a major growth engine.
- Steady US generics business with incremental launches.
- Biosimilar pipeline targeting a $50 billion addressable market.
- Continued investments in specialty and biologics portfolio.
Related Earnings
Official Sources
Shubham Chaudhary is the founder of PositionalCalls, an independent Indian stock market research website. He writes company fundamentals, quarterly results analysis, IPO analysis and sector research for NSE and BSE listed companies, with a focus on banking stocks, insurance and long-term value investing. Every article is built from primary sources such as RBI, SEBI, NSE and BSE filings and company annual reports, and states its risks plainly in simple language for retail investors.
Coverage areas Our research standards- Numbers checked against NSE, BSE and SEBI filings
- Risks and limits stated in every article
- No paid promotions or broker tie-ups
- Articles updated when new filings arrive